日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase I study of MAGE-A1-targeted T1367 T-cell receptorbased cell therapy in patients with advanced multiple myeloma

一项针对晚期多发性骨髓瘤患者的MAGE-A1靶向T1367 T细胞受体细胞疗法的I期研究

Krüger, Josefine; Obenaus, Matthias; Blau, Igor Wolfgang; Hoser, Dana; Vaegler, Martin; Rauschenbach, Hana; Anagnostopoulos, Ioannis; Jöhrens, Korinna; Scheuplein, Vivian; Kieback, Elisa; Böhme, Judith; Von Brünneck, Ann-Christin; Krönke, Jan; Busse, Antonia; Willimsky, Gerald; Blankenstein, Thomas; Pezzutto, Antonio; Keller, Ulrich; Nogai, Axel

Advanced disease and CD8(+) TEMRA cells predict severe infections in multiple myeloma

多发性骨髓瘤患者的晚期疾病和 CD8(+) TEMRA 细胞可预测严重感染。

Tranter, Eva; Busch, David; Heck, Clarissa; Blau, Igor Wolfgang; Nogai, Axel; Schiele, Phillip; Meisel, Christian; Bullinger, Lars; Frentsch, Marco; Na, Il-Kang

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

伊沙妥昔单抗、卡非佐米、来那度胺和地塞米松联合治疗高危新诊断多发性骨髓瘤

Leypoldt, Lisa B; Tichy, Diana; Besemer, Britta; Hänel, Mathias; Raab, Marc S; Mann, Christoph; Munder, Markus; Reinhardt, Hans Christian; Nogai, Axel; Görner, Martin; Ko, Yon-Dschun; de Wit, Maike; Salwender, Hans; Scheid, Christof; Graeven, Ullrich; Peceny, Rudolf; Staib, Peter; Dieing, Annette; Einsele, Hermann; Jauch, Anna; Hundemer, Michael; Zago, Manola; Požek, Ema; Benner, Axel; Bokemeyer, Carsten; Goldschmidt, Hartmut; Weisel, Katja C

The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities

多发性骨髓瘤的蛋白质基因组图谱揭示了疾病生物学和治疗机遇的奥秘

Evelyn Ramberger ,Valeriia Sapozhnikova ,Yuen Lam Dora Ng ,Anna Dolnik ,Matthias Ziehm ,Oliver Popp ,Eric Sträng ,Miriam Kull ,Florian Grünschläger ,Josefine Krüger ,Manuela Benary ,Sina Müller ,Xiang Gao ,Arunima Murgai ,Mohamed Haji ,Annika Schmidt ,Raphael Lutz ,Axel Nogai ,Jan Braune ,Dominik Laue ,Christian Langer ,Cyrus Khandanpour ,Florian Bassermann ,Hartmut Döhner ,Monika Engelhardt ,Christian Straka ,Michael Hundemer ,Dieter Beule ,Simon Haas ,Ulrich Keller ,Hermann Einsele ,Lars Bullinger ,Stefan Knop ,Philipp Mertins ,Jan Krönke

Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial

在接受大剂量硼替佐米治疗且符合移植条件的初诊多发性骨髓瘤患者中,接受硼替佐米治疗前后的疗效:来自 III 期 HOVON-65/GMMG-HD4 试验的 10 年以上随访后的长期总生存期

Mai, Elias K; Nogai, Axel; Lokhorst, Henk M; van der Holt, Bronno; Zweegman, Sonja; Weisel, Katja C; Croockewit, Sandra; Jauch, Anna; Hillengass, Jens; Stevens-Kroef, Marian; Raab, Marc S; Broijl, Annemiek; Bos, Gerard M J; Brossart, Peter; Ypma, Paula; Hanoun, Christine; Bertsch, Uta; Hielscher, Thomas; Salwender, Hans J; Scheid, Christoph; Goldschmidt, Hartmut; Sonneveld, Pieter

Real-world analysis of teclistamab in 123 RRMM patients from Germany

德国123例复发/难治性多发性骨髓瘤患者接受teclistamab真实世界分析

Riedhammer, C; Bassermann, F; Besemer, B; Bewarder, M; Brunner, F; Carpinteiro, A; Einsele, H; Faltin, J; Frenking, J; Gezer, D; Goldman-Mazur, S; Hänel, M; Hoegner, M; Kortuem, K M; Krönke, J; Kull, M; Leitner, T; Mann, C; Mecklenbrauck, R; Merz, M; Morgner, A; Nogai, A; Raab, M S; Teipel, R; Wäsch, R; Rasche, L

Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma

伊沙妥昔单抗联合卡非佐米、来那度胺和地塞米松治疗高危新诊断多发性骨髓瘤患者的简明语言摘要

Leypoldt, Lisa B; Tichy, Diana; Besemer, Britta; Hanel, Mathias; Raab, Marc S; Mann, Christoph; Munder, Markus; Reinhardt, Hans Christian; Nogai, Axel; Gorner, Martin; Ko, Yon-Dschun; de Wit, Maike; Salwender, Hans; Scheid, Christof; Graeven, Ullrich; Peceny, Rudolf; Staib, Peter; Dieing, Annette; Einsele, Hermann; Jauch, Anna; Hundemer, Michael; Zago, Manola; Pozek, Ema; Benner, Axel; Bokemeyer, Carsten; Goldschmidt, Hartmut; Weisel, Katja C

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

伊沙妥昔单抗联合硼替佐米、来那度胺和地塞米松治疗不适合/无立即进行自体干细胞移植的新诊断多发性骨髓瘤患者的疗效和安全性

Ocio, Enrique M; Perrot, Aurore; Bories, Pierre; San-Miguel, Jesus F; Blau, Igor W; Karlin, Lionel; Martinez-Lopez, Joaquin; Wang, Song-Yau; Bringhen, Sara; Marcatti, Magda; Mateos, María-Victoria; Rodriguez-Otero, Paula; Oliva, Stefania; Nogai, Axel; Le Roux, Nadia; Dong, Liyan; Macé, Sandrine; Gassiot, Matthieu; Fitzmaurice, Thomas; Oprea, Corina; Moreau, Philippe

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

SUMO化抑制可克服多发性骨髓瘤中的蛋白酶体抑制剂耐药性

Guus J J E Heynen, Francis Baumgartner, Michael Heider, Upayan Patra, Maximilian Holz, Jan Braune, Melanie Kaiser, Isabell Schäffer, Stefanos A Bamopoulos, Evelyn Ramberger, Arunima Murgai, Yuen Lam Dora Ng, Uta Margareta Demel, Dominik Laue, Sven Liebig, Josefine Krüger, Martin Janz, Axel Nogai, Ma

Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation

异基因造血干细胞移植后患者对新冠疫苗体液免疫反应的影响因素和特征

Hütter-Krönke, Marie Luise; Neagoie, Adela; Blau, Igor Wolfgang; Wais, Verena; Vuong, Lam; Gantner, Andrea; Ahn, Johann; Penack, Olaf; Schnell, Jacqueline; Nogai, Klaus Axel; Eberspächer, Bettina; Saadati, Maral; Benner, Axel; Bullinger, Lars; Döhner, Hartmut; Bunjes, Donald; Sala, Elisa